QSAM Biosciences (QSAM Biosciences) Interest Expense : $-0.40 Mil (TTM As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is QSAM Biosciences Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. QSAM Biosciences's interest expense for the three months ended in Dec. 2023 was $ 0.05 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.40 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. QSAM Biosciences's Operating Income for the three months ended in Dec. 2023 was $ -0.48 Mil. QSAM Biosciences's Interest Expense for the three months ended in Dec. 2023 was $ 0.05 Mil. QSAM Biosciences did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

QSAM Biosciences Interest Expense Historical Data

The historical data trend for QSAM Biosciences's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

QSAM Biosciences Interest Expense Chart

QSAM Biosciences Annual Data

Trend

Mar14

Mar15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.54

-0.99

-0.79

-0.07

-0.40

QSAM Biosciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															0.06	-0.44	-	-0.01	0.05

QSAM Biosciences Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.40 Mil.

QSAM Biosciences (OTCPK:QSAM) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

QSAM Biosciences's Interest Expense for the three months ended in Dec. 2023 was $0.05 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-0.48 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $0.00 Mil.

QSAM Biosciences's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

The higher the ratio, the stronger the company's financial strength is.

QSAM Biosciences (QSAM Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » QSAM Biosciences Inc (OTCPK:QSAM) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

9442 Capital of Texas Highway North, Plaza 1, Suite 500, Austin, TX, USA, 78759

Website

https://www.qsambio.com

QSAM Biosciences Inc is a clinical-stage novel radiopharmaceutical company. The company is developing treatments for bone cancer and related diseases.

Executives

Adam King	officer: Chief Financial Officer	9442 CAPITAL OF TEXAS HWY N, PLAZA 1, SUITE 500, AUSTIN TX 78759
Link Jr. Charles J	director	C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AIMES IA 50010
Adriann Sax	director	7 DORSET COURT,, EAST BRUNSWICK, NJ 08816
David Charles Link	director	2100 E 54TH STREET NORTH, SIOUX FALLS SD 57104
Douglas R Baum	director, officer: CEO & Director	5000 RAFFEE COVE, AUSTIN TX 78731-1132
C Richard Piazza	director, officer: Executive Chairman	2236 EAST MALL, SUITE 208, UNIVERSITY OF BRITISH COLUMBIA, VANCOUVER A1 V6T 1Z3
Checkmate Strategic Capital Holdings, Llc	other: Member of 13(d) 10% owner grp	595 E. COLORADO BOULEVARD, SUITE 530, PASADENA CA 91101
Checkmate Strategic Capital 2, Llc	10 percent owner, other: See Explanation of Responses	595 E. COLORADO BOULEVARD, SUITE 530, PASADENA CA 91101
Checkmate Capital Group, Llc	10 percent owner, other: Member of 13(d) 10% owner grp	595 E. COLORADO BOULEVARD, SUITE 530, PASADENA CA 91101
Charles Thomas Paschall	other: Member of 13(d) 10% owner grp	595 E. COLORADO BOULEVARD, SUITE 530, PASADENA CA 91101
Christopher M. Nelson	director, officer: General Counsel	420 ROYAL PALM WAY, SUITE #100, PALM BEACH FL 33480
Scott W. Whitney	director, other: Former Director	96 WINDSOR DRIVE, PINE BROOK NJ 07058
Kevin Bolin	director, officer: Former Chairman & CEO	1081 ROSEDALE DRIVE, ATLANTA GA 30306
Tristan Peitz	director, other: Former Director	C/O Q2POWER TECHNOLOGIES, INC., 420 ROYAL PALM WAY, #100, PALM BEACH FL 33480
Joel David Mayersohn	director	350 EAST LAS OLAS BLVD. #1150, FORT LAUDERDALE FL 33301